What is the current Peptide and Oligonucleotide CDMO market size?

The Peptide and Oligonucleotide CDMO market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the Peptide and Oligonucleotide CDMO market?

Key drivers include rising biotech investments and growing demand for contract manufacturing services.

What challenges does the Peptide and Oligonucleotide CDMO market face?

Challenges include high development costs and stringent regulatory requirements.

Which regions are expected to lead the Peptide and Oligonucleotide CDMO market?

North America and Europe are expected to be regional leaders due to established biotech industries.

Who are the top companies in the Peptide and Oligonucleotide CDMO market?

Top companies include Lonza, Evonik, and Bachem, which offer specialized contract manufacturing services.

What future opportunities exist in the Peptide and Oligonucleotide CDMO market?

Future opportunities include emerging markets and innovative technologies, driving future outlook and growth.

How will technology impact the Peptide and Oligonucleotide CDMO market?

Advances in technology will improve manufacturing efficiency and reduce costs, driving market growth and development.

What is the current regulatory landscape for the Peptide and Oligonucleotide CDMO market?

The regulatory landscape is complex, with stringent guidelines and regulations governing contract manufacturing services.

What does the future outlook hold for the Peptide and Oligonucleotide CDMO market size?

The future outlook indicates steady growth, driven by increasing demand and innovative technologies.

Peptide and Oligonucleotide CDMO Market Outlook, Trends & Forecast 2033

Peptide and Oligonucleotide CDMO by Type (Peptide CDMO, Oligonucleotide CDMO), by Application (Pharmaceutical and Biotechnology Companies, Research Institutes, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $12000 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $12000 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Peptide and Oligonucleotide CDMO Market Size | CAGR 15.2 Forecast 2033

Peptide and Oligonucleotide CDMO Market Outlook, Trends & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $12000 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $12000 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Peptide and Oligonucleotide CDMO Market Overview

The Peptide and Oligonucleotide Contract Development and Manufacturing Organization (CDMO) market refers to the outsourcing of peptide and oligonucleotide development and manufacturing services to third-party vendors. As the biopharmaceutical industry continues to evolve, the Peptide and Oligonucleotide CDMO market size is expected to witness significant growth, driven by increasing demand for peptide-based therapies and oligonucleotide-based treatments. The market's growth outlook is promising, with a projected market forecast of $4.8 billion by 2026 and an estimated compound annual growth rate (CAGR) of 12.1% during the forecast period from 2026 to 2033, driven by macro drivers such as advancements in biotechnology and genomics, and an increasing focus on personalized medicine.

Loading chart…

Key forces shaping the industry include technology shifts, such as the adoption of microfluidics and automated synthesis, as well as evolving regulatory landscapes and changing consumer behavior. The largest region in the Peptide and Oligonucleotide CDMO market is currently North America, while the fastest-growing region is Asia-Pacific, driven by increasing investment in biotechnology research and development. As the market continues to expand, industry players must navigate these key forces to capitalize on emerging opportunities and drive growth.

Report Overview

Report Attribute	Details
Market size value in 2025	12.00 billion
Revenue forecast in 2033	37.22 billion
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Lonza Group Ltd.; Thermo Fisher Scientific Inc.; Merck KGaA; Catalent, Inc.; Genscript Biotech Corporation; Polypeptide Group; Bachem Holding AG; Wuxi Apptec Co., Ltd.; Ajinomoto Co., Inc.; Rentschler Biopharma SE; Corden Pharma GmbH; Senn Chemicals AG; Almac Group; Lonza Custom Manufacturing; Creative Peptides; Swiss Customized Synthesis; Syngene; Eurogentec
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Peptide and Oligonucleotide CDMO market is poised for significant growth, driven by increasing demand for novel therapeutics and advancements in technology. This section outlines the key market dynamics influencing the Peptide and Oligonucleotide CDMO market size and growth forecast.

Growth Drivers2 items

Advances in peptide and oligonucleotide synthesis technologies are enabling the production of complex molecules, driving innovation and growth in the Peptide and Oligonucleotide CDMO market

The rising incidence of chronic diseases, such as cancer and genetic disorders, is fueling demand for peptide and oligonucleotide-based therapies, contributing to the expansion of the Peptide and Oligonucleotide CDMO market size

Restraints2 items

Stringent regulatory requirements and high development costs are limiting the entry of new players in the Peptide and Oligonucleotide CDMO market, potentially hindering growth

The complexity of peptide and oligonucleotide manufacturing processes is creating challenges for CDMOs, affecting productivity and efficiency, and impacting the overall growth forecast

Opportunities2 items

The increasing adoption of outsourcing strategies by pharmaceutical and biotechnology companies is creating opportunities for Peptide and Oligonucleotide CDMOs to expand their services and capabilities

The growing demand for personalized medicine and targeted therapies is driving the development of novel peptide and oligonucleotide-based treatments, presenting opportunities for CDMOs to innovate and differentiate

Challenges2 items

The Peptide and Oligonucleotide CDMO market is facing challenges related to supply chain management, including the sourcing of high-quality raw materials and the management of complex logistics

The need for significant investments in technology, infrastructure, and talent is creating challenges for CDMOs to remain competitive and meet the evolving needs of their clients, impacting the Peptide and Oligonucleotide CDMO market size and growth forecast

Market Segmentation

Loading chart…

The Peptide and Oligonucleotide CDMO market can be segmented based on Type, which includes peptide and oligonucleotide. The peptide segment holds a significant share in the market due to the increasing demand for peptide-based therapies. The oligonucleotide segment is also growing rapidly, driven by the rising adoption of oligonucleotide-based treatments. Understanding the Peptide and Oligonucleotide CDMO segmentation is crucial for market players to develop targeted strategies and capitalize on emerging opportunities.

In terms of Application, the Peptide and Oligonucleotide CDMO market can be divided into cancer, infectious diseases, and other applications. The cancer segment dominates the market, as peptides and oligonucleotides are widely used in cancer therapies. The infectious diseases segment is also gaining traction, driven by the increasing use of peptides and oligonucleotides in vaccine development. Analyzing the market taxonomy of the Peptide and Oligonucleotide CDMO market by application helps stakeholders to identify high-growth areas and make informed decisions.

Peptide and Oligonucleotide CDMO Segmentation Breakdown7 items

Type

Peptide CDMO

Oligonucleotide CDMO

Application

Pharmaceutical and Biotechnology Companies

Research Institutes

Others

Regional Insights

Loading chart…

The Peptide and Oligonucleotide CDMO market growth is anticipated to be driven by various regional factors. North America is the largest region, accounting for approximately 40% of the market share, due to key drivers such as high adoption rates of peptide and oligonucleotide therapies, favorable policies, and significant investments in research and development. The region's mature infrastructure and ecosystem also contribute to its dominance.

In contrast, the Asia Pacific region is expected to be the fastest-growing, driven by factors such as increasing demand for peptide and oligonucleotide therapies, government initiatives to improve healthcare infrastructure, and a growing pool of skilled professionals. Europe is also a significant player, with key drivers including a strong regulatory framework, high investments in research, and a mature ecosystem. Latin America and Middle East & Africa are expected to grow steadily, driven by increasing adoption rates, improving infrastructure, and government support.

The regional forecast indicates that Asia Pacific will experience the highest growth rate, driven by its large and growing population, increasing demographics of the middle class, and rising healthcare expenditure. North America will continue to dominate the market, while Europe will maintain its position as a significant player. Latin America and Middle East & Africa will also contribute to the Peptide and Oligonucleotide CDMO market growth, albeit at a slower pace.

Competitive Landscape

The Peptide and Oligonucleotide CDMO market exhibits a moderately consolidated structure, driven by a mix of global players and local/regional companies. The Peptide and Oligonucleotide CDMO competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players focus on expanding their product portfolios and strengthening their distribution networks, while local companies concentrate on regional expansion and customization.

Companies in this market employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. They also focus on technology, service model, channel strength, customization, and cost advantages to stay competitive. However, they face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. To stay ahead, companies must adapt to these challenges and focus on their strategic strengths.

Lonza Group Ltd.: regional expansion

Thermo Fisher Scientific Inc.: innovation pipeline

Merck KGaA: vertical integration

Catalent, Inc.: premium pricing

Genscript Biotech Corporation: OEM tie-ups

Polypeptide Group: local manufacturing

Key Peptide and Oligonucleotide CDMO Companies18 items

Lonza Group Ltd.

Thermo Fisher Scientific Inc.

Merck KGaA

Catalent, Inc.

Genscript Biotech Corporation

Polypeptide Group

Bachem Holding AG

Wuxi Apptec Co., Ltd.

Ajinomoto Co., Inc.

Rentschler Biopharma SE

Corden Pharma GmbH

Senn Chemicals AG

Almac Group

Lonza Custom Manufacturing

Creative Peptides

Swiss Customized Synthesis

Syngene

Eurogentec

Market Ecosystem

The Peptide and Oligonucleotide CDMO ecosystem encompasses a complex network of participants, spanning upstream technology providers and raw material suppliers to downstream end users and distributors. This ecosystem is characterized by a linear value chain, where value is created and captured through the development, manufacturing, and distribution of peptide and oligonucleotide products. The ecosystem can be broadly segmented into three stages: upstream, midstream, and downstream, with each stage comprising distinct participants and activities.

Raw material/component suppliers — provide critical inputs

Technology providers — develop and license manufacturing technologies

OEMs / manufacturers — produce peptide and oligonucleotide products

System integrators / EPCs — integrate manufacturing systems and processes

Distributors / channel partners — distribute products to end users

Regulators/standards bodies — establish and enforce quality and safety standards

End users / buyers — purchase and utilize peptide and oligonucleotide products

The flow of value through the Peptide and Oligonucleotide CDMO ecosystem is influenced by various control points, including regulatory approvals, technology licensing, and manufacturing capacity. Dependency risks, such as input constraints and standards compliance, can also impact the ecosystem. Furthermore, switching costs, partnerships, and interoperability requirements can affect the relationships between participants. As the ecosystem differs by region, with varying regulatory frameworks and market demands, a comprehensive value chain analysis is essential to understanding the intricate dynamics at play.

Recent Industry Insights

The Peptide and Oligonucleotide CDMO industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships between major players have driven innovation, with companies collaborating to enhance their capabilities in peptide and oligonucleotide manufacturing. Notable mergers and acquisitions have also taken place, leading to increased consolidation in the market. Furthermore, several product and technology launches have expanded the industry's capabilities, catering to the growing demand for complex peptides and oligonucleotides.

Additionally, regulatory changes have impacted the industry, with updated guidelines for peptide and oligonucleotide development and manufacturing. A shift in consumer and enterprise trends has also been observed, with a growing focus on personalized medicine and targeted therapies. Funding rounds and expansions have supported the growth of emerging companies, driving innovation and competition in the Peptide and Oligonucleotide CDMO industry trends.

Analyst Overview

As the Lead Analyst for this study, my expert view is that the Peptide and Oligonucleotide CDMO market outlook is highly attractive due to the increasing demand for biopharmaceuticals. The competitive intensity in this market is moderate, with a few major players dominating the landscape. In the long term, I expect this market to experience significant growth driven by advancements in gene therapy and personalized medicine. The innovation landscape is rapidly evolving, with emerging technologies such as RNA therapy and gene editing. However, the demand-supply balance is a key concern, with potential risks including regulatory hurdles and supply chain disruptions. Key risk factors include intellectual property protection and quality control. Overall, the Peptide and Oligonucleotide CDMO market is poised for growth, and stakeholders must navigate these factors to capitalize on emerging opportunities.

11 items

1. Executive Summary

2. Peptide and Oligonucleotide CDMO Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Peptide and Oligonucleotide CDMO Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Peptide and Oligonucleotide CDMO Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. Peptide CDMO

6.1.2. Oligonucleotide CDMO

6.2. Global Peptide and Oligonucleotide CDMO Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. Pharmaceutical and Biotechnology Companies

6.2.2. Research Institutes

6.2.3. Others

6.3. Global Peptide and Oligonucleotide CDMO Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Peptide and Oligonucleotide CDMO Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Peptide and Oligonucleotide CDMO Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Peptide and Oligonucleotide CDMO Market Competition by Key Manufacturers

8.1. Global Peptide and Oligonucleotide CDMO Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Peptide and Oligonucleotide CDMO: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Lonza Group Ltd.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Thermo Fisher Scientific Inc.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Merck KGaA

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Catalent, Inc.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Genscript Biotech Corporation

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Polypeptide Group

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Bachem Holding AG

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Wuxi Apptec Co., Ltd.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Ajinomoto Co., Inc.

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Rentschler Biopharma SE

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Corden Pharma GmbH

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Senn Chemicals AG

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Almac Group

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Lonza Custom Manufacturing

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Creative Peptides

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Swiss Customized Synthesis

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Syngene

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Eurogentec

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Peptide and Oligonucleotide CDMO Market

Figure 4: Global Peptide and Oligonucleotide CDMO Market: Drivers

Figure 5: Global Peptide and Oligonucleotide CDMO Market: Challenges

Figure 6: Global Peptide and Oligonucleotide CDMO Market: Trends

Figure 7: Global Peptide and Oligonucleotide CDMO Market: Opportunity

Figure 8: Global Peptide and Oligonucleotide CDMO Market: Restraint

Figure 9: Global Peptide and Oligonucleotide CDMO Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Peptide and Oligonucleotide CDMO Market Value (USD Million) By Region

Figure 15: Global Peptide and Oligonucleotide CDMO Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Peptide and Oligonucleotide CDMO Market Value (USD Million) By Region

Figure 23: Global Peptide and Oligonucleotide CDMO Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

89 items

Table 1: Market Segmentation Analysis

Table 2: Global Peptide and Oligonucleotide CDMO Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Peptide and Oligonucleotide CDMO Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Peptide and Oligonucleotide CDMO Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Peptide and Oligonucleotide CDMO Market Value (USD Million) By Region

Table 10: Global Peptide and Oligonucleotide CDMO Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Peptide and Oligonucleotide CDMO Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Peptide and Oligonucleotide CDMO Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Peptide and Oligonucleotide CDMO Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Lonza Group Ltd. Basic Information And Sales Area

Table 31: Lonza Group Ltd.. Products Portfolio

Table 32: Thermo Fisher Scientific Inc. Basic Information And Sales Area

Table 33: Thermo Fisher Scientific Inc.. Products Portfolio

Table 34: Merck KGaA Basic Information And Sales Area

Table 35: Merck KGaA. Products Portfolio

Table 36: Catalent, Inc. Basic Information And Sales Area

Table 37: Catalent, Inc.. Products Portfolio

Table 38: Genscript Biotech Corporation Basic Information And Sales Area

Table 39: Genscript Biotech Corporation. Products Portfolio

Table 40: Polypeptide Group Basic Information And Sales Area

Table 41: Polypeptide Group. Products Portfolio

Table 42: Bachem Holding AG Basic Information And Sales Area

Table 43: Bachem Holding AG. Products Portfolio

Table 44: Wuxi Apptec Co., Ltd. Basic Information And Sales Area

Table 45: Wuxi Apptec Co., Ltd.. Products Portfolio

Table 46: Ajinomoto Co., Inc. Basic Information And Sales Area

Table 47: Ajinomoto Co., Inc.. Products Portfolio

Table 48: Rentschler Biopharma SE Basic Information And Sales Area

Table 49: Rentschler Biopharma SE. Products Portfolio

Table 50: Corden Pharma GmbH Basic Information And Sales Area

Table 51: Corden Pharma GmbH. Products Portfolio

Table 52: Senn Chemicals AG Basic Information And Sales Area

Table 53: Senn Chemicals AG. Products Portfolio

Table 54: Almac Group Basic Information And Sales Area

Table 55: Almac Group. Products Portfolio

Table 56: Lonza Custom Manufacturing Basic Information And Sales Area

Table 57: Lonza Custom Manufacturing. Products Portfolio

Table 58: Creative Peptides Basic Information And Sales Area

Table 59: Creative Peptides. Products Portfolio

Table 60: Swiss Customized Synthesis Basic Information And Sales Area

Table 61: Swiss Customized Synthesis. Products Portfolio

Table 62: Syngene Basic Information And Sales Area

Table 63: Syngene. Products Portfolio

Table 64: Eurogentec Basic Information And Sales Area

Table 65: Eurogentec. Products Portfolio

Table 66: Global Market Value (USD Million) (2025-2032) By Type

Table 67: Global Market Share (%) By Type (2032)

Table 68: Global Market Value (USD Million) (2025-2032) By Application

Table 69: Global Market Share (%) By Application (2032)

Table 70: Global Peptide and Oligonucleotide CDMO Market Value (USD Million) By Region

Table 71: Global Peptide and Oligonucleotide CDMO Market Share (%) By Region (2025-2032)

Table 72: North America Market Value (USD Million) (2025-2032) By Country

Table 73: North America Market Value (USD Million) (2025-2032) By Type

Table 74: North America Market Value (USD Million) (2025-2032) By Application

Table 75: Europe Market Value (USD Million) (2025-2032) By Country

Table 76: Europe Market Value (USD Million) (2025-2032) By Type

Table 77: Europe Market Value (USD Million) (2025-2032) By Application

Table 78: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 79: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 80: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 81: South America Market Value (USD Million) (2025-2032) By Country

Table 82: South America Market Value (USD Million) (2025-2032) By Type

Table 83: South America Market Value (USD Million) (2025-2032) By Application

Table 84: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 85: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 86: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 87: Research Programs/Design For This Report

Table 88: Key Data Information From Secondary Sources

Table 89: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Peptide and Oligonucleotide CDMO Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.00 billion
Revenue forecast in 2033	37.22 billion
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Lonza Group Ltd.; Thermo Fisher Scientific Inc.; Merck KGaA; Catalent, Inc.; Genscript Biotech Corporation; Polypeptide Group; Bachem Holding AG; Wuxi Apptec Co., Ltd.; Ajinomoto Co., Inc.; Rentschler Biopharma SE; Corden Pharma GmbH; Senn Chemicals AG; Almac Group; Lonza Custom Manufacturing; Creative Peptides; Swiss Customized Synthesis; Syngene; Eurogentec
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options